ClinicalTrials.gg
TerminatedNCT02524847Updated Sep 11, 2020Results posted

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

A Phase 3 interventional study of Methoxsalen and Extracorporeal Photopheresis (ECP) in Steroid Refractory Acute Graft Versus Host Disease, sponsored by Therakos, Inc., a Mallinckrodt Company. Terminated at 32 sites in 8 countries. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2020-09-11.

Sponsored by Therakos, Inc., a Mallinckrodt Company · Phase 3, Interventional, and Treatment

Why this study was terminated
Slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
209th of 389
29 · median 30
Started
2016
with 15 others
Phase 3
40 of 454
2 open now
Registered
302nd of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 209th largest by enrollment of the 389 interventional ones that give a count, is one of 16 that started in 2016, is one of 40 in phase 3, and was the 302nd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen) Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems (ECP) in pediatric participants with steroid-refractory aGvHD. The study is composed of Screening, Treatment, and Follow-up Periods.

Read the detailed description

Screening:

After the informed consent/assent form (ICF) is signed, the screening assessments will be performed in a single visit to establish the eligibility of the participant, based on inclusion and exclusion criteria, as well as aGvHD grading. Scheduling of the first week of ECP treatments and the arrangements for availability of typed and cross-matched donor packed red blood cells (PRBCs) for transfusion, if required, will be made in advance of participants entering the Treatment Period.

Treatment Period:

Once eligibility is established, participants will enter the 12-week ECP Treatment Period. The availability of typed and cross-matched donor PRBCs for transfusion during treatment, if needed, should be established prior to the scheduling of ECP treatments.

Participants will be allowed to continue standard aGvHD prophylaxis regimens (e.g., cyclosporine, tacrolimus, methotrexate, mycophenolate mofetil) without the addition of new therapies. Participants will be allowed to discontinue prophylaxis regimens for reasons of toxicity, and will also be allowed to switch to another prophylaxis medication within the same class (e.g., the calcineurin inhibitors cyclosporine and tacrolimus) for reasons of toxicity.

All participants enrolled in this trial will have received corticosteroids for the treatment of aGvHD. After entering the treatment period on study, tapering of steroids by total weekly decrements of 12.5% to 25% of the steroid dose at initiation of ECP therapy is permitted after a sustained response of aGvHD has been observed for at least 3 consecutive days, with the suggested goal to decrease the starting steroid dose by at least 50% 4 weeks after initiation of ECP.

Follow-Up Period:

After completion of the 12-week Treatment Period, participants may continue ECP treatment on commercial product at the Principal Investigator's discretion. Acute GvHD status will be assessed 4 weeks after completion of the Treatment Period. Participant survival will be assessed by passive follow-up (chart review) 26 weeks after initiation of ECP treatment.

03

Conditions studied

  • Steroid Refractory Acute Graft Versus Host Disease

Browse trials for

04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 1 to 21 years of age at the time of consent
  2. - grade B-D aGvHD.

    • Steroid-refractory is defined as a failure to respond to steroid treatment, with failure to respond defined as any grade B-D (IBMTR grading) aGvHD that shows progression ≥ 3 days, or no improvement by 5 days of treatment with 2 mg/kg/day methylprednisolone or equivalent in participants with lower gastrointestinal (GI) or liver disease, or skin disease associated with bullae. Grade D organ involvement will be limited to skin and liver.
    • Steroid refractory may also be defined as a failure to respond to 1 mg/kg/day of methylprednisolone or equivalent in participants with disease confined to upper GI disease or lesser degrees of skin GvHD
    • Participants with lack of complete response after 2 weeks of steroid treatment
  3. A Lansky scale Performance Status score ≥ 30
  4. Laboratory values are within the following limits, assessed within 3 days of the first study treatment:

    • > 0.5 × 10\^9/liter (L)
    • Creatinine level \< 2 times the
  5. For participants with isolated upper GI symptoms, pre-Screening results to confirm diagnosis of aGvHD
  6. Female participants of and nonsterilized males who are sexually active with a female partner must be practicing highly effective, reliable, and medically approved regimen throughout their participation in the study and for 3 months following the last ECP treatment. Or, for the US only, abstinence may be used in place of an approved contraceptive regimen. Females of childbearing potential are those who have reached the onset of menarche, or 8 years of age, whichever comes first. Approved contraceptive methods for female participants of childbearing potential or nonsterilized males who are sexually active with a female partner are as follows:

    • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
    • Established use of oral, injectable, or implanted hormonal methods of contraception.
    • Placement of an intrauterine device or intrauterine system
  7. Signed /assent is obtained before conducting any study procedures; the parent, legal guardian, or legally authorized representative of a minor must also provide written informed consent

Exclusion criteria

Exclusion:

  1. Currently enrolled in another clinical trial for the treatment of aGvHD
  2. Use of any experimental regimens or medication(s) for aGvHD treatment
  3. Treatment with > 2.0 mg/kg/day of methylprednisolone equivalents for aGvHD within 30 days prior to the first study treatment
  4. Overt signs of relapse of the underlying condition
  5. Uncontrolled viral, fungal, or bacterial infection
  6. count \< 20.0 × 10\^9/L, despite platelet transfusion
  7. Inability to tolerate the extracorporeal volume shifts associated with ECP treatment
  8. Uncontrolled GI bleeding
  9. Veno-occlusive liver disease
  10. \< 4 weeks
  11. Participant requires invasive ventilation or vasopressor support
  12. Known (HIV) or or C virus infection (proof of seronegativity within 6 months of screening is required)
  13. Known allergy or to methoxsalen, Uvadex, or its
  14. Known hypersensitivity and allergy to heparin and Anticoagulant Citrate Dextrose Formula-A (ACD-A)
  15. Co-existing photosensitive disease (e.g., porphyria, systemic lupus erythematosus, albinism) or aphakia
  16. Coagulation disorders that cannot be corrected with simple transfusion
  17. Co-existing melanoma, basal cell, or squamous cell skin carcinoma
  18. Previous splenectomy
  19. White blood cell count greater than 25,000 cubic millimeter (mm\^3)
  20. Currently being treated with any systemic or biologic therapy for the treatment of a medical condition other than aGvHD
  21. Female participant is breastfeeding or pregnant
  22. Any medical concerns that may pose risk to the participant
  23. Any psychological, familial, sociological, and/or geographical condition that may potentially hamper compliance with the study protocol and follow-up schedule
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Methoxsalen with ECP

    Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.

    Drug: Methoxsalen · Procedure: Extracorporeal Photopheresis (ECP)

Interventions

  • Sterile solution used in conjunction with photopheresis procedure.

    Also known as: UVADEX®

  • ProcedureExtracorporeal Photopheresis (ECP)

    Also known as: THERAKOS® CELLEX® Photopheresis System

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at Week 4

    OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows: * CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment * PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment

    Time frame: 4 weeks

Secondary outcomes

  1. Number of Participants With Adverse Events

    Clinically significant changes in vital signs, laboratory values and investigations are reported as adverse events. Summary data are provided below, with details listed in the adverse events module.

    Time frame: 16 weeks

  2. Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 8

    OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows: * CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment * PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment

    Time frame: 8 weeks

  3. Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 12

    OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows: * CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment * PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment

    Time frame: 12 weeks

  4. Duration of Response (Days) Within 16 Weeks Using Modified IBMTR Severity Index

    Duration of first response is presented for patients whose disease progressed. Duration of response is defined in the following way: Patients whose response failed: Date at which 1st disease progression occurs - date of 1st response +1. Patients whose response did not relapse: Date of 16 week follow-up or final assessment prior to week 16 (if patient withdrew early) - date of 1st response.

    Time frame: 16 weeks

  5. Overall Response Rate (ORR) According to the Modified Glucksberg Criteria

    ORR is defined as the percentage of patients who achieve an overall response after 4 weeks, 8 weeks, and 12 weeks of ECP treatment according to a scoring algorithm applied to calculate the grade of aGvHD using the modified Glucksberg Criteria.

    Time frame: 4 weeks, 8 weeks, and 12 weeks

  6. Cumulative Dose of Daily Steroids

    Steroids administered from diagnosis of aGvHD to 12 Weeks after initiation of ECP treatment

    Time frame: From diagnosis of aGvHD to 12 Weeks

  7. Number of Patients With Skin Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

    Number of patients whose skin was rated as Stage 0 - 4 using the modified Glucksberg criteria based on the Graft versus Host Disease (GvHD) rash - Stages are defined as 0=No GvHD rash, 1=Maculopapular rash on \<25% body surface area (BSA), 2=Maculopapular rash on 25-50% BSA, 3=Maculopapular rash on \>50% BSA, and 4=Generalized erythroderma plus bullous formation, which are blisters bigger than 5 mm across

    Time frame: at 4, 8 and 12 weeks

  8. Number of Patients With Liver Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

    Number of patients whose liver was rated as Stage 0 - 4 on the modified Glucksberg criteria - Stages are based on level of bilirubin, defined as: Stage 0 = Bilirubin \< 2.0 mg/dL, Stage 1 = Bilirubin 2.0-3.0 mg/dL, Stage 2 = Bilirubin 3.1-6.0 mg/dL, Stage 3 = Bilirubin 6.1-15.0 mg/dL, and Stage 4 = Bilirubin \> 15.0 mg/dL

    Time frame: at 4, 8 and 12 weeks

07

Results

Posted Sep 11, 2020
Limitations and caveats
This study did have a notable limitation in its single-group study design. This may limit a more robust assessment vs standard of care alone for primary endpoint of overall response and secondary endpoints steroid sparing and disease progression.

Participant flow

Participant flow — Overall Study
MilestoneMethoxsalen With ECP
Started29
Completed treatment up to week 1214
Started second line treatment5
Completed15
Not completed14
Withdrew: Adverse event4
Withdrew: Unsatisfactory therapeutic effect4
Withdrew: Condition no longer requires treatment4
Withdrew: Death1
Withdrew: Reason not specified1

Outcome measures

PrimaryNumber of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at Week 4

OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows: * CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment * PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at Week 4
ParticipantsMethoxsalen With ECP
Number of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at Week 416
Statistical analysis
  • Methoxsalen With ECP · t-test, 2 sided · p = <.001 · Overall response rate (%): 55.2 · 95% CI 35.7 to 73.62-sided p-value for testing the null hypothesis H0: Standard therapy has a CR+PR rate = 10% after 4 weeks, using the exact Binomial test.
SecondaryNumber of Participants With Adverse Events

Clinically significant changes in vital signs, laboratory values and investigations are reported as adverse events. Summary data are provided below, with details listed in the adverse events module.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsMethoxsalen With ECP
Any serious AE12
Non-serious TEAE at 5% threshold17
Death for any cause3
SecondaryPercentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 8

OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows: * CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment * PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 8
percentage of participantsMethoxsalen With ECP
Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 873.7 (48.8 to 90.9)
SecondaryPercentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 12

OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows: * CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment * PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 12
percentage of participantsMethoxsalen With ECP
Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 1278.6 (49.2 to 95.3)
SecondaryDuration of Response (Days) Within 16 Weeks Using Modified IBMTR Severity Index

Duration of first response is presented for patients whose disease progressed. Duration of response is defined in the following way: Patients whose response failed: Date at which 1st disease progression occurs - date of 1st response +1. Patients whose response did not relapse: Date of 16 week follow-up or final assessment prior to week 16 (if patient withdrew early) - date of 1st response.

Time frame:
16 weeks
Reported as:
Median · days
Duration of Response (Days) Within 16 Weeks Using Modified IBMTR Severity Index
daysMethoxsalen With ECP
Duration of Response (Days) Within 16 Weeks Using Modified IBMTR Severity Index13.5 (4 to 50)
SecondaryOverall Response Rate (ORR) According to the Modified Glucksberg Criteria

ORR is defined as the percentage of patients who achieve an overall response after 4 weeks, 8 weeks, and 12 weeks of ECP treatment according to a scoring algorithm applied to calculate the grade of aGvHD using the modified Glucksberg Criteria.

Time frame:
4 weeks, 8 weeks, and 12 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) According to the Modified Glucksberg Criteria
percentage of participantsMethoxsalen With ECP
Week 450 (29.1 to 70.9)
Week 863.2 (38.4 to 83.7)
Week 1278.6 (49.2 to 95.3)
SecondaryCumulative Dose of Daily Steroids

Steroids administered from diagnosis of aGvHD to 12 Weeks after initiation of ECP treatment

Time frame:
From diagnosis of aGvHD to 12 Weeks
Reported as:
Median · mg
Cumulative Dose of Daily Steroids
mgMethoxsalen With ECP
Cumulative Dose of Daily Steroids1917 (192 to 6895)
SecondaryNumber of Patients With Skin Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

Number of patients whose skin was rated as Stage 0 - 4 using the modified Glucksberg criteria based on the Graft versus Host Disease (GvHD) rash - Stages are defined as 0=No GvHD rash, 1=Maculopapular rash on \<25% body surface area (BSA), 2=Maculopapular rash on 25-50% BSA, 3=Maculopapular rash on \>50% BSA, and 4=Generalized erythroderma plus bullous formation, which are blisters bigger than 5 mm across

Time frame:
at 4, 8 and 12 weeks
Reported as:
Count of participants · Participants
Number of Patients With Skin Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria
ParticipantsAll Participants
Week 4 — Stage 09
Week 4 — Stage 18
Week 4 — Stage 23
Week 4 — Stage 33
Week 4 — Stage 40
Week 8 — Stage 011
Week 8 — Stage 15
Week 8 — Stage 21
Week 8 — Stage 31
Week 8 — Stage 40
Week 12 — Stage 010
Week 12 — Stage 12
Week 12 — Stage 21
Week 12 — Stage 31
Week 12 — Stage 40
SecondaryNumber of Patients With Liver Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

Number of patients whose liver was rated as Stage 0 - 4 on the modified Glucksberg criteria - Stages are based on level of bilirubin, defined as: Stage 0 = Bilirubin \< 2.0 mg/dL, Stage 1 = Bilirubin 2.0-3.0 mg/dL, Stage 2 = Bilirubin 3.1-6.0 mg/dL, Stage 3 = Bilirubin 6.1-15.0 mg/dL, and Stage 4 = Bilirubin \> 15.0 mg/dL

Time frame:
at 4, 8 and 12 weeks
Reported as:
Count of participants · Participants
Number of Patients With Liver Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria
ParticipantsAll Participants
Week 4 — Stage 019
Week 4 — Stage 11
Week 4 — Stage 21
Week 4 — Stage 30
Week 4 — Stage 40
Week 8 — Stage 013
Week 8 — Stage 10
Week 8 — Stage 20
Week 8 — Stage 30
Week 8 — Stage 40
Week 12 — Stage 012
Week 12 — Stage 10
Week 12 — Stage 20
Week 12 — Stage 30
Week 12 — Stage 40

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Methoxsalen With ECP3/29 (10.3%)12/29 (41.4%)17/29 (58.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventMethoxsalen With ECP
PyrexiaGeneral disorders2/29
Acute graft versus host diseaseImmune system disorders2/29
AspergillomaInfections and infestations1/29
Bk virus infectionInfections and infestations1/29
CellulitisInfections and infestations1/29
Cystitis viralInfections and infestations1/29
Cytomegalovirus infectionInfections and infestations1/29
Device related infectionInfections and infestations1/29
Hepatitis EInfections and infestations1/29
General physical health deteriorationGeneral disorders1/29
Most frequent other events
Showing 10 of 17
Most frequent other events
EventMethoxsalen With ECP
Abdominal painGastrointestinal disorders4/29
NauseaGastrointestinal disorders4/29
HypertensionVascular disorders4/29
CoughRespiratory, thoracic and mediastinal disorders4/29
HyperglycaemiaMetabolism and nutrition disorders3/29
HypocalcaemiaMetabolism and nutrition disorders3/29
HypotensionVascular disorders3/29
PyrexiaGeneral disorders3/29
HypogammaglobulinaemiaImmune system disorders3/29
HyperkalaemiaMetabolism and nutrition disorders2/29

Baseline characteristics

Safety Analysis Set included all participants who receive any amount of study drug.

Age, Continuous
Age, Continuous(years)Methoxsalen With ECP
Mean8.6 ± 5.02
Sex: Female, Male
Sex: Female, Male(Participants)Methoxsalen With ECP
Female12
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Methoxsalen With ECP
Hispanic or Latino5
Not Hispanic or Latino24
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Methoxsalen With ECP
Asian1
Black or African American2
White22
Other4
08

Study locations

32 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Children's Healthcare of Atlanta, Emory - Children's Center
    Atlanta, Georgia 30322, United States
  • Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University Hospitals Rainbow Babies & Children's
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Children's
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Vanderbilt University Medical Center - Ingram Cancer Institute
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Care Center
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • St Anna Kinderspital
    Wien, 1090, Austria
  • Hopital Necker Enfants Malades
    Paris, 75015, France
  • Hôpital universitaire Robert Debré
    Paris, 75019, France
  • Universitätsklinikum Leipzig, Klinik und Poliklinik für Kinder- und Jugendmedizin, Abteilung für Hämatologie und Internistische Onkologie
    Leipzig, 04103, Germany
  • Klinikum rechts der Isar, TU München, Klinik- und Poliklinik für Kinder- und Jugendmedizin, Kinderklinik München Schwabing
    München, 80804, Germany
  • University Hospital Tuebingen
    Tübingen, 72076, Germany
  • Universitaetsklinikum Ulm, Kinder- und Jugendmedizin
    Ulm, 89075, Germany
  • United St Istvan and St Laszlo Hospital
    Budapest, 1097, Hungary
  • U.O.C. Clinica di Oncoematologia Pediatrica Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Pediatric Hospital Bambinu Gesu Rome
    Rome, 00165, Italy
  • Vall d'Hebron University Hospital
    Barcelona, 8035, Spain
  • Hospital Infantil Universitario "Nino Jesus"
    Madrid, 28009, Spain
  • University Hospital Salamanca
    Salamanca, 37007, Spain
  • Hospital LA FE
    Valencia, 46026, Spain
  • Great North Children's Hospital (RVI)
    Newcastle, NE1 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Because we work in the rare disease space, to eliminate risk of patient identification we do not share individual patient data. We post summary aggregate results for applicable clinical trials in the registry, and statistical endpoints and discussion in publications; with each referencing the other.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Jul 2019, 41 months.

Results were first posted in Sep 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2015
First posted
Aug 17, 2015
StartActual
Jan 20, 2016
Primary completionActual
Jul 16, 2019
CompletionActual
Jul 16, 2019
Results first posted
Sep 11, 2020
Last update
Sep 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02524847
Lead sponsor
Therakos, Inc., a Mallinckrodt Company
Responsible party
Sponsor
First posted
Aug 17, 2015
Start date
Jan 20, 2016
Primary completion
Jul 16, 2019
Completion
Jul 16, 2019
Results posted
Sep 11, 2020
Last update
Sep 11, 2020

Study contacts

Clinical Team Leader
study director · Mallinckrodt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion